[Economic evaluation of the use of haematopoietic factors in managing malignant hemopathies].
Economic evaluation of haematopoietic growth factors in the treatment of malignant hemopathies was undertaken along with clinical trials or retrospectives studies. The cost of the sole treatment was estimated to be 2,302 US$ per cycle. Cost-minimization analyses compared the cost of a treatment course (chemotherapy, bone marrow transplantation with and without haematopoietetic growth factors), and cost-effectiveness analyses estimated the cost per episode of averted febrile neutropenia. Results appear to be contradictory and do not allow definite conclusions about the existence of extra costs or of cost savings due to the introduction haematopoietetic growth factors, except in the case of filgrastim-mobilized peripheral blood progenitor cell transplantation.
Durand-Zaleski
I
I
Santé publique, HITEQ, hôpital Henri-Mondor, Créteil, France.
Chaix
C
C
D003362:Cost-Benefit Analysis; D005602:France; D019337:Hematologic Neoplasms / Q000191:economics* / Q000628:therapy; D016298:Hematopoietic Cell Growth Factors / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D017053:Infection Control
D016298:Hematopoietic Cell Growth Factors